Alendronic acid/guanidine dextran conjugate - DexTech Medical AB

Drug Profile

Alendronic acid/guanidine dextran conjugate - DexTech Medical AB

Alternative Names: Alendronate/dextran/guanidine; Osteodex

Latest Information Update: 12 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator DexTech Medical
  • Class Antihypercalcaemics; Antineoplastics; Antithrombotics; Bisphosphonates; Calcium regulators; Drug conjugates; Glucans; Plasma expanders; Small molecules
  • Mechanism of Action Adrenergic receptor agonists; Osteoclast inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Bone metastases

Most Recent Events

  • 29 Jun 2016 Discontinued - Phase-II for Bone metastases (In the elderly, Metastatic disease, In adults) in Denmark (IV) (NCT02825628)
  • 01 May 2016 DexTech Medical initiates a phase II trial for Bone metastases (In adults, In the elderly, Metastatic disease) in Sweden (IV) (NCT02825628)
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top